New Blood Test Detects Early Alzheimer’s Through Protein Changes

A recent study has introduced a promising method for early detection of Alzheimer’s disease through a novel blood test that analyses structural changes in plasma proteins. Published in “Nature Aging”, the research highlights how alterations in protein folding, rather than their quantity, could serve as early biological markers of the disease.

Innovative Approach to Alzheimer’s Diagnosis

Unlike conventional diagnostic methods that focus on amyloid plaques and tau tangles in the brain, this new technique examines how amino acids fold within proteins circulating in the blood. Researchers analysed plasma samples from over 500 individuals and identified distinct structural differences in specific proteins associated with Alzheimer’s and mild cognitive impairment.

Role of Proteostasis in Disease Progression

The study is based on the concept of proteostasis, the biological system responsible for maintaining proper protein folding and eliminating damaged proteins. As individuals age, this system becomes less efficient, leading to misfolded proteins. Such disruptions are believed to contribute significantly to neurodegenerative diseases like Alzheimer’s.

Key Protein Markers Identified

The research identified three critical proteins—C1QA (immune signalling), clusterin (protein folding and amyloid removal), and apolipoprotein B (fat transport and vascular health). Structural changes in these proteins were strongly linked to disease stages. Advanced machine learning techniques were used to detect patterns, enabling accurate differentiation between healthy individuals, those with mild cognitive impairment, and Alzheimer’s patients.

Important Facts for Exams

• Alzheimer’s disease is associated with amyloid plaques and tau tangles in the brain.
• Proteostasis refers to maintenance of proper protein folding in cells.
• Clusterin helps in protein folding and removal of amyloid deposits.
• Machine learning is increasingly used in medical diagnostics.

Implications for Early Detection and Treatment

The findings suggest that analysing structural changes in plasma proteins could provide a more sensitive and early diagnostic tool compared to traditional methods. Early detection is crucial for timely intervention and improving treatment outcomes. This approach may also enhance clinical trials by identifying patients at earlier stages of the disease, offering new hope in the fight against Alzheimer’s.